Publication: Bardoxolone Methyl Analog Attenuates Proteinuria-Induced Tubular Damage by Modulating Mitochondrial Function

Dihydro-CDDO-trifluoroethyl amide (dh404), a rodent-tolerable bardoxolone methyl analog, significantly reduced proteinuria-induced tubular cell mitochondrial damage in a model of diabetic kidney disease.

  • Treatment with bardoxolone methyl analog improved mitochondrial function, suppressed inflammatory signaling, and reduced oxidative stress.
  • Treatment with bardoxolone methyl analog was protective of the renal tubular interstitium, decreased fibrosis, and preserved kidney function despite not improving proteinuria.